BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase
The delivery of the cladribine API enables the commencement of clinical batch manufacturing in collaboration with BioNxt's European contract research and development partner, Gen-Plus GmbH & Co KG, based in Munich, Germany. This milestone supports the company's plan to initiate a human bioequivalence study in the second half of 2025.
BNT23001 is designed to offer a patient-friendly alternative to traditional oral cladribine tablets, such as Mavenclad®, by providing a rapidly dissolving sublingual film. This delivery method aims to enhance patient compliance, particularly for individuals with MS who experience dysphagia, a common symptom affecting the ability to swallow.
Preclinical studies have demonstrated that BNT23001 achieves high absorption rates and bioequivalence to existing oral therapies, with no adverse toxic effects observed. These findings support the progression to human bioequivalence studies.
BioNxt has also made significant strides in securing intellectual property rights for BNT23001. The company has initiated patent nationalization processes in key jurisdictions, including Europe, the United States, and Canada, with patent grants anticipated by mid-2025.
'The receipt of the cladribine API is a pivotal step forward in our mission to develop innovative, patient-centric therapies for MS,' said Hugh Rogers, CEO of BioNxt Solutions. 'We are committed to advancing BNT23001 through clinical development and bringing this novel treatment option to patients worldwide.'
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next‐generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin‐Film), Transdermal (Skin Patch), and Oral (Enteric‐Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient‐centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com .
Investor Relations & Media Contact
Hugh Rogers, Co‐Founder, CEO and Director
Email: [email protected]
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt‐solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding 'Forward‐Looking' Information
This news release includes certain statements that may be deemed 'forward-looking statements'. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words 'expects', 'plans', 'anticipates', 'believes', 'intends', 'estimates', 'projects', 'potential' and similar expressions, or that events or conditions 'will', 'would', 'may', 'could' or 'should' occur. Forward-looking information in this news release includes the anticipated filing date of the Annual Filings. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
SOURCE: BioNxt Solutions Inc.
press release
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
11 minutes ago
- Bloomberg
Gold Miner Aura Minerals Seeks $210 Million in US Listing
Aura Minerals Inc. is seeking to raise about $210 million in a US listing, as the gold and copper miner looks to expand its investor base. The company, which already trades on exchanges in Canada and Brazil, will offer 8.1 million shares in the deal, according to a filing Monday with the US Securities and Exchange Commission. The listing is set to price on July 15, according to terms of the deal seen by Bloomberg News.
Yahoo
an hour ago
- Yahoo
Atrium Mortgage Investment Corporation Announces July 2025 Dividend
Toronto, Ontario--(Newsfile Corp. - July 7, 2025) - Atrium Mortgage Investment Corporation (TSX: AI) is pleased to announce that its board of directors has declared a dividend for the month of July 2025 of $0.0775 per common share, to be paid August 12, 2025 to shareholders of record July 31, 2025. Atrium pays monthly dividends currently at an annual rate of $0.93 per share, plus a special dividend to shareholders of record at year end in the event the dividends declared are less than taxable income for that fiscal year. Shareholders are reminded that Atrium offers a dividend reinvestment plan (DRIP) that allows them to automatically reinvest their dividends in new shares of Atrium at a 2% discount from market price and with no commissions. This provides shareholders with an easy way to realize the benefits of compound growth of their investment in Atrium. Shareholders can enroll in the DRIP program by contacting their investment advisor. About Atrium Canada's Premier Non-Bank Lender™ Atrium is a non-bank provider of residential and commercial mortgages that lends in major urban centres in Canada where the stability and liquidity of real estate are high. Atrium's objectives are to provide its shareholders with stable and secure dividends and preserve shareholders' equity by lending within conservative risk parameters. Atrium is a Mortgage Investment Corporation (MIC) as defined in the Canada Income Tax Act, so is not taxed on income provided that its taxable income is paid to its shareholders in the form of dividends within 90 days after December 31 each year. Such dividends are generally treated by shareholders as interest income, so that each shareholder is in the same position as if the mortgage investments made by the company had been made directly by the shareholder. For further information, please refer to regulatory filings available at or Atrium's website at For further information, please contact Robert G. Goodall Chief Executive Officer Gigi WongChief Financial Officer (416) 867-1053info@ To view the source version of this press release, please visit


Bloomberg
an hour ago
- Bloomberg
Carney's Cabinet Searches for Spending Cuts as Defense Bill Grows
Canada's finance minister has asked members of cabinet to find tens of billions of dollars in spending cuts as the government looks for ways to pay for a larger defense budget and capital projects. Finance Minister Francois-Philippe Champagne asked ministers to identify how to cut 7.5% from program spending for the 2026-27 fiscal year, which begins next April, according to two officials with knowledge of the matter.